Venetoclax in combination with HMAs both upfront and in the relapsed/ refractory setting

Clinical Pearls Podcasts published on March 16, 2020
Download Transcript Download Podcast
Shyamala C. Navada, MD, MSCR
Assistant Professor
Mount Sinai School of Medicine
Department of Medicine
Division of Hematology/Oncology
New York, New York

There were many exciting abstracts at this year's ASH related to MDS. One drug that we've been using quite a bit in acute myeloid leukemia that's now being studied in MDS is venetoclax in combination with HMAs, both upfront and in the relapsed/refractory setting, and I think this combination would give us another option to use in higher-risk MDS patients. Another drug that I think has an exciting mechanism and the data looked promising was the anti-CD47 medication, also used in combination with HMAs. In addition, we know that p53 mutations are a poor prognostic factor in MDS patients and the combination of APR-246 with HMA also was an exciting part of this year's ASH publications as related to MDS.

Last modified: March 6, 2020
Related Items by Author
What are the current unmet educational needs for the treatment of MDS?
Shyamala C. Navada, MD, MSCR
Clinical Pearls Podcasts published on March 30, 2020

MediCom Worldwide, Inc. would like to thank Celgene Corporation and Onconova Therapeutics Inc. for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved